Researcher Regina M. Graham at the University of Miami Miller School of Medicine led a study exploring the potential of carbon dots (CDs) in treating pediatric brain tumors. These highly adaptable nanoparticles can be modified to target cancer cells more effectively while reducing toxicity, addressing key challenges such as the blood-brain barrier and tumor heterogeneity. With promising pre-clinical results, CDs represent an innovative approach in the ongoing search for safer and more effective pediatric brain tumor treatments.
We are proud to partner with the University of Miami and some truly amazing and talented individuals to make these research trials possible. We invite you to explore this page to learn about all the incredible, groundbreaking research funded by the Live Like Bella Pediatric Cancer Research Initiative that will help make pediatric cancer a treatable and curable disease.
David Robbins
Novel Regulators of SHH-driven Medulloblastoma.
Claudia Rodrigues
Novel Mechanisms of Anthracycline-Induced Cardiomyopathy.
Brian Marples
Maintaining Renal Function After Total Body Irradiation.
David Robbins
Designing New Strategies for Most Lethal Forms of Medulloblastoma.
Matteo Trucco
Enhancing Immunotherapy Through Inhibition of CAIX to Treat Osteosarcoma.
Julio Barredo, MD
Targeting Compensatory Survival Responses at the Intersection of Energy Metabolism and Epigenetics in Acute Lymphoblastic Leukemia.
Claes Wahlestedt
Development of an IDE Submission for Drug Sensitivity Testing Platform for Pediatric Sarcoma Treatment Stratification.
Paulo Pinheiro
The role of prenatal exposures and specific ethnicity on childhood cancer disparities in Florida.
Regina Graham
Carbon Dot derivative for bimodal imaging and targeted drug delivery to pediatric high-grade gliomas.
Anis Ahmad
Preventing treatment-induced nephrotoxicity in pediatrics cancer survivors.
Warren Alperstein
Investigating the impact of demographic factors on the development of GVHD.
Julio Barredo, MD
AMP Activated Protein Kinase (AMPK) Regulates Survival Responses at the Convergence of Energy Metabolism and Epigenetics in Acute Lymphoblastic Leukemia.
Surinder Kumar, PhD
SIRT7 as a novel therapeutic target in Ewing Sarcoma.